Details of proposed European PFAS ban released Today, the European Chemicals Agency (ECHA) published details of a proposed ban on the production, use, sale and import of some 10,000 per- and polyfluoroalkyl substances (PFAS).
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Incidence of infections that cause gastrointestinal symptoms on the rise again In 2021, the incidence of enteric infections – which mainly cause gastrointestinal symptoms – was higher than in 2020, but still lower than before the coronavirus pandemic. This is the outcome of a study into enteric infections and pathogens transmitted from animals to humans.
PFAS levels in drinking water from river water need to be brought down The National Institute for Public Health and the Environment (RIVM) advises to reduce PFAS concentrations in the drinking water in parts of the Netherlands in the coming years. This concerns drinking water produced from river water.
Hypersensitivity reactions to fillers may occur after COVID-19 vaccination People may experience hypersensitivity reactions to fillers following a COVID-19 vaccination.
Chromium-6 from medical implants not harmful to health Chromium-6 from medical implants, such as hip or knee implants, does not result in severe health damage.
Most reports received by MEBI in 2021 concerned copper IUDs More reports of suspected adverse effects from copper intrauterine devices (IUDs) were made in 2021 than in previous years, according to the annual report of the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI).
Shortcomings in the technical documentation of mesh implants intended to treat pelvic organ prolapse used in the Netherlands After a detailed assessment of the technical documentation of 9 different mesh implants intended to treat pelvic organ prolapse used in NL (2018) RIVM concludes that the safety and performance of these products were not properly substantiated.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).